

# Emanuele D'Amico

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1194545/publications.pdf>

Version: 2024-02-01

97  
papers

3,225  
citations

236612

25  
h-index

174990

52  
g-index

98  
all docs

98  
docs citations

98  
times ranked

5062  
citing authors

#	ARTICLE	IF	CITATIONS
1	Injectable versus oral first-line multiple sclerosis therapies: knows and unknowns from observational studies. <i>Neural Regeneration Research</i> , 2022, 17, 567.	1.6	5
2	Spinal needle and post-dural puncture headache. <i>Neurological Sciences</i> , 2022, 43, 1467-1468.	0.9	1
3	Immunological Subsets Characterization in Newly Diagnosed Relapsing-Remitting Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2022, 13, 819136.	2.2	5
4	Mesenchymal Stem Cell-Derived Extracellular Vesicles and Their Therapeutic Use in Central Nervous System Demyelinating Disorders. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3829.	1.8	7
5	Stopping Interferon Beta 1b Does Not Influence the Risk of Disability Accrual in Non-Active SPMS: Results from an Italian Real-World Study. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 6069.	1.2	1
6	The Dysphagia in Multiple Sclerosis Questionnaire Correlates with Fiber-Optic Endoscopic Examination for Detecting Swallowing Deficits in MS. <i>Dysphagia</i> , 2021, 36, 192-197.	1.0	10
7	Exploring polypharmacy phenomenon in newly diagnosed relapsing-remitting multiple sclerosis: a cohort ambispective single-centre study. <i>Therapeutic Advances in Chronic Disease</i> , 2021, 12, 204062232098312.	1.1	16
8	Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register. <i>Neurotherapeutics</i> , 2021, 18, 905-919.	2.1	9
9	Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study. <i>Neurotherapeutics</i> , 2021, 18, 1166-1174.	2.1	24
10	Male fertility in relapsing-remitting multiple sclerosis patients treated with natalizumab and ocrelizumab: A prospective case-control study. <i>Multiple Sclerosis Journal</i> , 2021, 27, 2284-2287.	1.4	8
11	Dietary Phenolic Acids and Their Major Food Sources Are Associated with Cognitive Status in Older Italian Adults. <i>Antioxidants</i> , 2021, 10, 700.	2.2	25
12	Metabolic Abnormalities, Dietary Risk Factors and Nutritional Management in Amyotrophic Lateral Sclerosis. <i>Nutrients</i> , 2021, 13, 2273.	1.7	25
13	First-line therapies in late-onset multiple sclerosis: An Italian registry study. <i>European Journal of Neurology</i> , 2021, 28, 4117-4123.	1.7	17
14	Exit-strategies in Natalizumab-treated RRMS at high risk of progressive multifocal leukoencephalopathy: A multicentre comparison study. <i>Journal of the Neurological Sciences</i> , 2021, 429, 117769.	0.3	0
15	First-line therapies in late onset multiple sclerosis: An Italian registry study. <i>Journal of the Neurological Sciences</i> , 2021, 429, 118090.	0.3	0
16	Lack of association between <i>Toxocara canis</i> and multiple sclerosis: A population-based case-control study. <i>Multiple Sclerosis Journal</i> , 2020, 26, 258-259.	1.4	3
17	Prevalence of dysphagia in a consecutive cohort of subjects with MS using fibre-optic endoscopy. <i>Neurological Sciences</i> , 2020, 41, 1075-1079.	0.9	13
18	Mental health status of relapsing-remitting multiple sclerosis Italian patients returning to work soon after the easing of lockdown during COVID-19 pandemic: A monocentric experience. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102561.	0.9	24

#	ARTICLE	IF	CITATIONS
19	Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1160-1203.	6.3	890
20	Gonadal Steroids and Sperm Quality in a Cohort of Relapsing Remitting Multiple Sclerosis: A Case-Control Study. <i>Frontiers in Neurology</i> , 2020, 11, 756.	1.1	6
21	Toxoplasma gondii and multiple sclerosis: a population-based case–control study. <i>Scientific Reports</i> , 2020, 10, 18855.	1.6	12
22	Pharmacotherapeutic management of lower urinary tract symptoms in Multiple Sclerosis patients. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1449-1454.	0.9	11
23	Acetyl-L-Carnitine in Dementia and Other Cognitive Disorders: A Critical Update. <i>Nutrients</i> , 2020, 12, 1389.	1.7	52
24	Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis. <i>Journal of Neurology</i> , 2020, 267, 3008-3020.	1.8	19
25	Pregnancy and the Postpartum Period in Women With Relapsing-Remitting Multiple Sclerosis Treated With Old and New Disease-Modifying Treatments: A Real-World Multicenter Experience. <i>Frontiers in Neurology</i> , 2020, 11, 105.	1.1	8
26	CSF neurotoxic metals/metalloids levels in amyotrophic lateral sclerosis patients: comparison between bulbar and spinal onset. <i>Environmental Research</i> , 2020, 188, 109820.	3.7	17
27	Immunosuppression in relapsing remitting multiple sclerosis: moving towards personalized treatment. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 771-782.	1.4	6
28	An update on the pharmacological management of pain in patients with multiple sclerosis. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 2249-2263.	0.9	12
29	Changes in Anti-JCV Antibody Status in a Large Population of Multiple Sclerosis Patients Treated with Natalizumab. <i>CNS Drugs</i> , 2020, 34, 535-543.	2.7	6
30	Clinical and patient determinants of changing therapy in relapsing-remitting multiple sclerosis (SWITCH study). <i>Multiple Sclerosis and Related Disorders</i> , 2020, 42, 102124.	0.9	18
31	Silicon Photomultiplier Sensor Interface Based on a Discrete Second Generation Voltage Conveyor. <i>Sensors</i> , 2020, 20, 2042.	2.1	4
32	Prevalence and Incidence of Multiple Sclerosis in the City of Biancavilla. <i>Neuroepidemiology</i> , 2019, 53, 108-114.	1.1	6
33	An update on the safety of treating relapsing-remitting multiple sclerosis. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 925-948.	1.0	13
34	Are oligoclonal bands associated to lower retinal layer thickness at the time of relapsing remitting multiple sclerosis diagnosis? Evidence from an exploratory study. <i>Autoimmunity Reviews</i> , 2019, 18, 102365.	2.5	1
35	Monocytic Myeloid Derived Suppressor Cells in Hematological Malignancies. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5459.	1.8	17
36	The Neutrophil-to-Lymphocyte Ratio is Related to Disease Activity in Relapsing Remitting Multiple Sclerosis. <i>Cells</i> , 2019, 8, 1114.	1.8	40

#	ARTICLE	IF	CITATIONS
37	Pharmacoeconomics of synthetic therapies for multiple sclerosis. Expert Opinion on Pharmacotherapy, 2019, 20, 1331-1340.	0.9	8
38	New treatment targets in multiple sclerosis therapy. Expert Review of Precision Medicine and Drug Development, 2019, 4, 201-203.	0.4	0
39	Review: Patient-reported outcomes in multiple sclerosis care. Multiple Sclerosis and Related Disorders, 2019, 33, 61-66.	0.9	94
40	Placing CD20-targeted B cell depletion in multiple sclerosis therapeutic scenario: Present and future perspectives. Autoimmunity Reviews, 2019, 18, 665-672.	2.5	25
41	Cancer Risk and Multiple Sclerosis: Evidence From a Large Italian Cohort. Frontiers in Neurology, 2019, 10, 337.	1.1	26
42	Clinical, laboratory features, and prognostic factors in adult acute transverse myelitis: an Italian multicenter study. Neurological Sciences, 2019, 40, 1383-1391.	0.9	11
43	A New Rail-to-Rail Second Generation Voltage Conveyor. Electronics (Switzerland), 2019, 8, 1292.	1.8	10
44	Management of dysphagia in multiple sclerosis: current best practice. Expert Review of Gastroenterology and Hepatology, 2019, 13, 47-54.	1.4	20
45	Effectiveness and safety of Rituximab in demyelinating diseases spectrum: An Italian experience. Multiple Sclerosis and Related Disorders, 2019, 27, 324-326.	0.9	35
46	Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience. Journal of Neurology, 2019, 266, 411-416.	1.8	20
47	Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS. Multiple Sclerosis Journal, 2019, 25, 591-600.	1.4	13
48	Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study. Multiple Sclerosis Journal, 2019, 25, 399-407.	1.4	38
49	Comparison of genioglossus muscle activity and efficiency of dexmedetomidine or propofol during drug-induced sleep endoscopy in patients with obstructive sleep apnea/hypopnea syndrome. European Review for Medical and Pharmacological Sciences, 2019, 23, 389-396.	0.5	4
50	Hopelessness in Multiple Sclerosis: Psychological and Organic Correlates. Journal of Psychiatry and Psychiatric Disorders, 2019, 03, .	0.0	5
51	Lateral switch to IFN beta-1a 44 mcg may be effective as escalation switch to fingolimod in selected persons with relapsing remitting multiple sclerosis: a real-world setting experience. Expert Review of Clinical Pharmacology, 2018, 11, 531-536.	1.3	4
52	Identifying neuropathic pain in patients with multiple sclerosis: a cross-sectional multicenter study using highly specific criteria. Journal of Neurology, 2018, 265, 828-835.	1.8	45
53	Pharmacokinetic drug evaluation of daclizumab for the treatment of relapsing-remitting multiple sclerosis. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 341-352.	1.5	1
54	Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641879640.	1.5	26

#	ARTICLE	IF	CITATIONS
55	Late-onset and young-onset relapsing-remitting multiple sclerosis: evidence from a retrospective long-term follow-up study. <i>European Journal of Neurology</i> , 2018, 25, 1425-1431.	1.7	47
56	Cognitive-motor dual-task interference: A systematic review of neural correlates. <i>Neuroscience and Biobehavioral Reviews</i> , 2017, 75, 348-360.	2.9	179
57	Can new chemical therapies improve the management of multiple sclerosis in children?. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 45-55.	0.9	1
58	To stop or not to stop disease modifying therapies in secondary progressive multiple sclerosis, that is the question. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 847-849.	1.4	9
59	The clinical value of Coop/Wonca charts in assessment of HRQoL in a large cohort of relapsing-remitting multiple sclerosis patients: Results of a multicenter study. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 17, 154-171.	0.9	4
60	Induction therapy for the management of early relapsing forms of multiple sclerosis. A critical opinion. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1553-1556.	0.9	8
61	Could autologous hematopoietic stem cell transplantation be considered a second-line treatment option in relapsing-remitting multiple sclerosis? A critical editorial. <i>Expert Review of Precision Medicine and Drug Development</i> , 2017, 2, 69-71.	0.4	1
62	Palliative care in progressive multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 123-127.	1.4	5
63	Access to home palliative care services in Italy: the experience of the "SAMOT Onlus" home care unit. <i>Expert Review of Quality of Life in Cancer Care</i> , 2017, 2, 233-234.	0.6	0
64	May baseline JCV status influence the MS clinical evolution during Natalizumab treatment? Evidence from a multicenter-2Â-years-prospective study. <i>Multiple Sclerosis and Demyelinating Disorders</i> , 2017, 2, .	1.1	1
65	Offspring Number Does Not Influence Reaching the Disability's Milestones in Multiple Sclerosis: A Seven-Year Follow-Up Study. <i>International Journal of Molecular Sciences</i> , 2016, 17, 234.	1.8	18
66	A Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1725.	1.8	27
67	Depressive Symptoms Correlate with Disability and Disease Course in Multiple Sclerosis Patients: An Italian Multi-Center Study Using the Beck Depression Inventory. <i>PLoS ONE</i> , 2016, 11, e0160261.	1.1	46
68	Personalized therapy in multiple sclerosis: state of art and future perspectives. <i>Expert Review of Precision Medicine and Drug Development</i> , 2016, 1, 353-360.	0.4	2
69	Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs. <i>Drug Safety</i> , 2016, 39, 1163-1174.	1.4	35
70	Risk factors in multiple sclerosis: a population-based case-control study in Sicily. Background and methods. <i>Neurological Sciences</i> , 2016, 37, 1931-1937.	0.9	13
71	Association Between Dietary Intake and Function in Amyotrophic Lateral Sclerosis. <i>JAMA Neurology</i> , 2016, 73, 1425.	4.5	74
72	Lateral and escalation therapy in relapsing-remitting multiple sclerosis: a comparative study. <i>Journal of Neurology</i> , 2016, 263, 1802-1809.	1.8	18

#	ARTICLE	IF	CITATIONS
73	Inpatient versus outpatient rehabilitation for multiple sclerosis patients: effects on disability and quality of life. <i>Multiple Sclerosis and Demyelinating Disorders</i> , 2016, 1, .	1.1	10
74	Negative prognostic impact of MRI spinal lesions in the early stages of relapsing&#x2014;remitting multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2016, 2, 205521731663156.	0.5	8
75	Can we define a rehabilitation strategy for cognitive impairment in progressive multiple sclerosis? A critical appraisal. <i>Multiple Sclerosis Journal</i> , 2016, 22, 581-589.	1.4	23
76	The Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retroprospective Study. <i>PLoS ONE</i> , 2016, 11, e0157721.	1.1	5
77	Disability may influence patient willingness to participate in decision making on first-line therapy in multiple sclerosis. <i>Functional Neurology</i> , 2016, 31, 21-3.	1.3	13
78	Monoclonal antibody therapy in multiple sclerosis: critical appraisal and new perspectives. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 251-268.	1.4	4
79	A critical appraisal of daclizumab use as emerging therapy in multiple sclerosis. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 1157-1168.	1.0	3
80	Oral drugs in multiple sclerosis therapy: an overview and a critical appraisal. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 803-824.	1.4	30
81	Pregnancy outcomes in multiple sclerosis patients previously treated with cyclophosphamide. <i>Acta Neurologica Scandinavica</i> , 2014, 130, e41-e44.	1.0	5
82	Genetic burden of common variants in progressive and bout-onset multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 802-811.	1.4	11
83	Familial clustering in Italian progressive-onset and bout-onset multiple sclerosis. <i>Neurological Sciences</i> , 2014, 35, 789-791.	0.9	8
84	Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis. <i>Free Radical Biology and Medicine</i> , 2013, 65, 509-527.	1.3	269
85	Cognitive impairment and &#x201c;invisible symptoms&#x201c;are not associated with CCSVI in MS. <i>BMC Neurology</i> , 2013, 13, 97.	0.8	6
86	Clinical evolution of pure upper motor neuron disease/dysfunction (PUMMD). <i>Muscle and Nerve</i> , 2013, 47, 28-32.	1.0	26
87	Prevalence of patient-reported dysphagia in multiple sclerosis patients: An Italian multicenter study (using the DYMUS questionnaire). <i>Journal of the Neurological Sciences</i> , 2013, 331, 94-97.	0.3	53
88	Multiple Sclerosis and CCSVI: A Population-Based Case Control Study. <i>PLoS ONE</i> , 2012, 7, e41227.	1.1	25
89	Frequency and severity of headache is worsened by Interferon- $\beta$ therapy in patients with multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2012, 125, 91-95.	1.0	38
90	Serum and CSF N-acetyl aspartate levels differ in multiple sclerosis and neuromyelitis optica. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 1355-1359.	0.9	29

#	ARTICLE	IF	CITATIONS
91	Quality of life, depression and fatigue in mildly disabled patients with relapsingâ€“remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGnitive) Tj ETQq1 1 0.784314 rgB43 Overlock	1.0	14
92	Treatment options of cognitive impairment in multiple sclerosis. <i>Neurological Sciences</i> , 2010, 31, 265-269.	0.9	24
93	Lithium carbonate in amyotrophic lateral sclerosis. <i>Neurology</i> , 2010, 75, 619-625.	1.5	90
94	Real-life impact of early interferon $\beta$ therapy in relapsing multiple sclerosis. <i>Annals of Neurology</i> , 2009, 66, 513-520.	2.8	132
95	Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience. <i>Neurological Sciences</i> , 2009, 30, 193-199.	0.9	68
96	The DYMUS questionnaire for the assessment of dysphagia in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2008, 269, 49-53.	0.3	85
97	Serum leptin levels in acromegalic patients before and during somatostatin analogs therapy. <i>Journal of Endocrinological Investigation</i> , 2003, 26, 1219-1224.	1.8	13